170 related articles for article (PubMed ID: 30209556)
1. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
[TBL] [Abstract][Full Text] [Related]
2. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
3. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
Cai MC; Cheng S; Wang X; Hu JD; Song YP; Huang YH; Yan ZX; Jiang YJ; Fang XS; Zheng XY; Dong LH; Ji MM; Wang L; Xu PP; Zhao WL
Genome Med; 2020 Apr; 12(1):41. PubMed ID: 32349779
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
[TBL] [Abstract][Full Text] [Related]
6. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
Jia B; Hu S; Yang J; Zhou S; Liu P; Qin Y; Gui L; Yang S; Lin H; Zhang C; Xing P; Wang L; Dong M; Zhou L; Sun Y; He X; Shi Y
Hematology; 2016 Oct; 21(9):536-41. PubMed ID: 27077778
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
8. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.
Li L; Zhang C; Zhang L; Li X; Wu JJ; Sun ZC; Fu XR; Wang XH; Chang Y; Wang R; Qiu YJ; Zhang MZ
Neoplasma; 2014; 61(2):225-32. PubMed ID: 24299319
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
Chihara D; Pro B; Loghavi S; Miranda RN; Medeiros LJ; Fanale MA; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Neelapu SS; Younes A; Fowler NH; Rodriguez MA; Wang M; Kwak LW; McLaughlin P; Dang NH; Oki Y
Br J Haematol; 2015 Nov; 171(4):509-16. PubMed ID: 26260306
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M
Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
[TBL] [Abstract][Full Text] [Related]
14. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.
Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ
Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
Li L; Duan W; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Young KH; Zhang M
Br J Haematol; 2017 Sep; 178(5):772-780. PubMed ID: 28597542
[TBL] [Abstract][Full Text] [Related]
16. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M
JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
Zhang L; Wang Y; Li X; Li L; Wang X; Sun Z; Wu J; Fu X; Zhang X; Yu H; Wang G; Chang Y; Yan J; Zhou Z; Wu X; Nan F; Li W; Zhang M
Int J Cancer; 2021 Mar; 148(6):1470-1477. PubMed ID: 33034052
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.
Liu X; Yang M; Wu M; Zheng W; Xie Y; Zhu J; Song Y; Liu W
Cancer Chemother Pharmacol; 2019 Mar; 83(3):443-449. PubMed ID: 30511217
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
